Dalargin trial after abdominal surgery completed, results not yet released
A trial called Dal-PROTECT tested dalargin, an investigational peptide, in 200 patients after major abdominal surgery. The study was completed in September 2026, but its results have not yet been released.
Added on today
Source: Dalargin trial after abdominal surgery completed; results not yet posted (x.com). Summary written with AI from the source and reviewed by rules; read the original.
What the research shows
According to a publication, the Dal-PROTECT trial studied dalargin, an analogue of leu-enkephalin, in 200 patients who had undergone major abdominal surgery. It was a randomized, blinded study with a placebo control, meaning participants were assigned to groups by chance and some received a placebo without knowing it. The study was completed in September 2026, but its results have not yet been released.
Dalargin is a peptide under investigation for protecting organs after surgery. Because no results have been published, it is not possible to know whether it has any effect or what its safety profile is. No conclusion about benefits can be drawn at this time. Once the data are released, they will need careful review to determine what they actually show.
What it means
What is known is that a clinical trial with 200 patients has been completed, with a rigorous design. What remains unknown is whether dalargin protects organs after surgery, since the results have not been published.
How to read it with care
This text does not replace a consultation. Anyone considering a change in diet, supplements or treatment should talk to a doctor or another qualified health professional.